Home | About us | Editorial Board | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionContact Us   |  Subscribe   |  Advertise   |  Login  Page layout
Wide layoutNarrow layoutFull screen layout
Lung India Official publication of Indian Chest Society  
  Users Online: 4083   Home Print this page  Email this page Small font size Default font size Increase font size
Year : 2019  |  Volume : 36  |  Issue : 6  |  Page : 525-533

Management of community-acquired bacterial pneumonia in adults: Limitations of current antibiotics and future therapies

1 Department of Respiratory Medicine, Centre for Chest and Respiratory Disease, BLK Super Speciality Hospital, New Delhi, India
2 Department of Respiratory Medicine, Deccan College of Medical Sciences, Hyderabad, Telangana, India
3 Department of Respiratory Medicine, Kunal Institute of Pulmonology, Hyderabad, Telangana, India
4 Department of Critical Care Medicine, Lilavati Hospital and Research Centre, Mumbai, Maharashtra, India
5 Department of Medical Affairs, Wockhardt Ltd., BKC, Mumbai, Maharashtra, India

Correspondence Address:
Dr. Jaishid Ahdal
Department of Medical Affairs, Wockhardt Ltd., BKC, Mumbai, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/lungindia.lungindia_38_19

Rights and Permissions

Community-acquired bacterial pneumonia (CABP) is one of the leading causes of morbidity and mortality in India and worldwide. Evidence indicates that Gram-positive, Gram-negative, and atypical bacteria are encountered with near-equal frequency. Despite guideline recommendations and antibiotic options for the management of CABP, burden of morbidity and mortality is high, which is attributable to a variety of factors. Failure of empirical therapy, probably because of insufficient microbial coverage, increasing bacterial resistance, and adverse effects of existing treatments, underlies the unsuccessful treatment of CABP, especially in India. Multiple novel therapies that have entered clinical development phases have potential to address some of these issues. This article discusses the current treatment guidelines in CABP, management limitations, and emerging potential treatment options in the management of CABP.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded370    
    Comments [Add]    

Recommend this journal